BERGEN, Norway, November 2, 2023, BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting final results from a clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) will … Read more
BERGEN, Norway, October 31, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib, a highly selective AXL inhibitor in combination with … Read more
BERGEN, Norway, October 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were presented during the European Society … Read more
BERGEN, Norway, October 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) … Read more
– Presentation available September 11, 2023 on BGBIO website – BERGEN, Norway, September 11, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for Non-Small Cell Lung Cancer (NSCLC), announcedtoday that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference held in New York … Read more
Bergen 25 August 2023: Reference is made to the publication of the Second quarter and first half 2023 Financial Report on the 23 of August at 07:00 CET. The Financial Report is updated to include the Board of Directors Responsibility statement and is attached to this announcement and on our website. AttachmentsPDF PDF
BERGEN, Norway, August 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and first half ended June 30, 2023, and provided a business update. A briefing by BerGenBio’s senior management team will take place … Read more
BERGEN, Norway, August 22, 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announcedtoday that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer (NSCLC) have been recently published and accepted for presentation at two upcoming … Read more
Bergen, Norway, 16 August 2023- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2023 on Wednesday 23 August 2023. The briefing will take place at the Conference “Vestland på Børs” at 10:45 am CEST … Read more
Bergen 29 June 2023: Reference is made to previous stock exchange announcements from BerGenBio ASA (“BerGenBio” or the “Company”) regarding the partially underwritten rights issue of up to 2,500,000,000 new shares (the “Offer Shares”) in the Company, raising gross proceeds of up to NOK 250 million (the “Rights Issue”). Reference is further made to the … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.